Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 32, Number 8—August 2026

Dispatch

Human Cases of Borrelia miyamotoi Disease, Slovenia, 2025

Author affiliation: University Medical Center Ljubljana, Ljubljana, Slovenia (P. Bogovič, F. Strle); University of Ljubljana, Ljubljana (J. Slunečko, M. Kodre, R. Kogoj, M. Brecl Jakob, M. Korva, E. Ružić-Sabljić)

Suggested citation for this article

Abstract

We identified human Borrelia miyamotoi infections in Slovenia in 2 of 337 adults with undifferentiated fever tested positive by metagenomic sequencing and PCR. Both patients reported recent local tick bites. The illness was mild and self-limited. Our findings underscore the need to consider this pathogen in evaluating fever after tick bite.

Borrelia miyamotoi is an emerging tickborne spirochete belonging to the relapsing fever group of Borrelia spp. It was first detected in Ixodes persulcatus ticks in Japan and formally described as a novel species in 1995 (1). The first human cases of B. miyamotoi disease were reported in Russia in 2011, establishing its clinical relevance as a human pathogen (2). Since then, B. miyamotoi has been identified in Ixodes ticks and documented in human cases throughout the Northern Hemisphere, including Asia, North America, and Europe (3).

In Europe, the prevalence of B. miyamotoi in I. ricinus ticks varies geographically; estimated prevalence is 1%–1.5% (3,4), and the reported prevalence up to 4% (5). In Slovenia, B. miyamotoi was detected in 8 (2%) of 398 tested I. ricinus ticks (6) and in 2% of tested small rodents (7). Seroprevalence studies have demonstrated B. miyamotoi antibodies in an average of 4.4% of tested persons; reported values were 0%–25.6% (3). However, the lack of a commercially available serologic assay limits comparability across studies. A previous study examined exposure to and infection with B. miyamotoi in the Netherlands and Sweden during 2007–2019 (8). A total of 2,160 participants, including healthy controls, persons with a recent tick bite, and patients with post–tick bite fever, were tested by multiantigen serologic assay. IgM or IgG seroprevalence was 1.0%–2.5% in healthy participants, 6.1%–8.9% in those reporting recent tick bites, and as high as 16.5% in febrile persons in Sweden.

By March 1, 2021, more than 500 cases of B. miyamotoi disease had been reported worldwide, primarily in Asia (particularly Russia) and North America, whereas 6 cases had been documented in Europe (3). A subsequent literature search through January 31, 2026, identified 3 additional cases in Europe (911); those cases originated from the Netherlands, Germany, Sweden, Austria, Norway, and Poland (3,911).

B. miyamotoi disease usually manifests as acute febrile illness with fatigue, headache, chills, myalgia, arthralgia, and nausea. Although the pathogen belongs to the relapsing fever group, recurrent febrile episodes occur in ≈10% of patients (3). Meningoencephalitis has been reported predominantly in immunocompromised patients (3,9,10,12). Here, we describe 2 cases of B. miyamotoi disease acquired and diagnosed in Slovenia.

The Study

Participants qualified for our study if they met the following criteria: adult patients with acute febrile illness (>38°C for >2 days), without localizing signs, who remained without diagnosis after standard laboratory testing and were evaluated at the Department of Infectious Diseases, University Medical Centre Ljubljana (Ljubljana, Slovenia), during 2021–2025. We analyzed archived EDTA blood samples from those patients using shotgun metagenomic sequencing (mNGS) as previously described (13). The National Medical Ethics Committee of the Republic of Slovenia approved the use of archived specimens (approval no. 0120-253/2023/3).

Figure

Phylogenetic analysis of 2 cases of Borrelia miyamotoi disease, Slovenia, 2025. Analysis was based on the 16S rRNA gene. We aligned consensus sequences (1,241-bp-long 16S rRNA sequences) using MAFFT version 7.490 (https://mafft.cbrc.jp/alignment/software) with a global alignment >1,000 iterations. We constructed the phylogenetic tree based on the multiple sequence alignment using IQ-TREE 2 version 2.2.0 (http://www.iqtree.org) with automatic model selection for tree inference and ultrafast bootstrapping with 1,000 iterations. Bold text indicates study sequences (GenBank accession nos. PZ362887 and PZ362888). We selected reference sequences to represent the European, Asian, and US B. miyamotoi clusters. We used B. burgdorferi (GenBank accession nos. NC_001318.1, NR_044732.2), B. afzelii (GenBank accession no. NR_104748.1) and B. garinii (GenBank accession no. NR_043413.1) as the outgroups. Numbers at nodes indicate bootstrap values. Scale bar indicates substitutions per site.

Figure. Phylogenetic analysis of 2 cases of Borrelia miyamotoidisease, Slovenia, 2025. Analysis was based on the 16S rRNA gene. We aligned consensus sequences (1,241-bp-long 16S rRNA sequences) using MAFFT...

We detected B. miyamotoi in 2 (0.6%) of 337 cases by mNGS. We confirmed the presence of B. miyamotoi in both samples by specific real-time PCR (2) and sequencing of the full-length 16S rRNA gene (Figure). In addition to the 2 cases of B. miyamotoi, we identified other pathogens among sequenced patients: parvovirus B19 (n = 3), Epstein-Barr virus (n = 1), tick-borne encephalitis virus (n = 1), Anaplasma phagocytophilum (n = 1), Neoehrlichia mikurensis (n = 1), and Spiroplasma ixodetis (n = 15).

Case 1 was in a 36-year-old man who sought care in July 2022 for a 3-day history of fever as high as 38 °C and moderate headache, accompanied by occasional dry cough and mild nausea. Three weeks earlier, he had removed 2 ticks and noticed no subsequent skin changes. His medical history was unremarkable, and he was not taking any regular medications. He had not traveled outside Slovenia in the preceding 6 months. In 2012, he had received the basic vaccination for tick-borne encephalitis.

At examination, he was afebrile (36°C); blood pressure was 111/73 mm Hg, pulse 50 bpm, and peripheral oxygen saturation 98%. Physical examination was unremarkable; the patient had no rash or meningeal signs. Laboratory testing revealed several abnormalities, including elevated inflammatory markers (C-reactive protein 61 mg/L [reference range <5 mg/L]; procalcitonin 1.93 µg/L [reference range <0.25 µg/L]), increased creatinine (127 µmol/L [reference range 49–90 µmol/L]), mild thrombocytopenia (136 × 109/L [reference range 150–410 × 109/L]), abnormal liver function tests (total bilirubin 68 µmol/L [reference range 3–22 µmol/L]; aspartate aminotransferase 0.99 µkat/L [reference range <0.52 µkat/L]; alanine aminotransferase 1.24 µkat/L [reference range <0.57 µkat/L]; γ-glutamyl transferase 1.24 µkat/L [reference range <0.63 µkat/L]), and increased lactate dehydrogenase (5.93 µkat/L [reference range <4.12 µkat/L]). Chest radiography findings were unremarkable. Molecular and serologic tests for A. phagocytophilum, hantaviruses (the patient sought care during an ongoing hantavirus outbreak in Slovenia), and SARS-CoV-2 were negative. IgM and IgG serology for Borrelia burgdorferi sensu lato were also negative. He received no antimicrobial therapy. At 2-month follow-up, he was clinically well, and laboratory abnormalities had resolved.

Case 2 was in a 31-year-old previously healthy woman who, in May 2025, experienced acute fever (38.5 °C), chills, nausea, severe frontotemporal headache (visual analogue scale 8/10), photophobia, neck and shoulder pain, and lower limb paresthesias. She had removed a tick 10 days earlier. She had not traveled outside Slovenia in the preceding 6 months.

At examination, she was alert and afebrile (35.9°C) and had unremarkable vital signs (blood pressure 101/62 mm Hg, heart rate 88 bpm, peripheral oxygen saturation 100%). Mild neck pain on anteflexion and horizontal nystagmus were observed; the remainder of the neurologic and physical examination was unremarkable. Laboratory testing showed elevated C-reactive protein (37 mg/L), leukopenia (leukocytes 3.2 × 109 cells/L [reference range 4–10 × 109 cells/L]) with lymphopenia (lymphocytes 0.46 × 109 cells/L [reference range 1.1–3.5 × 109 cells/L]), and mild anemia (hemoglobin 116 g/L [reference range 120–150 g/L]). Renal function test results, electrolytes, and coagulation parameters were within reference ranges. Molecular and serologic analyses for A. phagocytophilum, along with serologic testing for tick-borne encephalitis virus, and B. burgdorferi s.l. yielded negative results. She received treatment for symptoms only. At 1-month follow-up, she was asymptomatic, and her laboratory values were within reference ranges.

Conclusions

We report 2 confirmed human cases of B. miyamotoi disease in Slovenia, both locally acquired. Those cases add to the small but growing number reported in Europe and provide clinical confirmation of human infection in a region where B. miyamotoi has been documented in ticks. Both patients were immunocompetent adults who experienced a self-limiting febrile illness without neurologic complications and without relapses; neither was treated with antimicrobial drugs. Detection by mNGS, confirmed by B. miyamotoi–specific PCR, underscores the importance of molecular diagnostics for identifying emerging tickborne pathogens in patients with unexplained febrile illness.

Information on asymptomatic or self-limiting B. miyamotoi infections remains scarce. The true incidence of B. miyamotoi disease is unknown because of limited clinical awareness, nonspecific and often mild symptoms, and restricted availability of diagnostic tools (3). In Slovenia, where tick-borne encephalitis and human granulocytic anaplasmosis represent the most common febrile illnesses after tick bites (14,15), clinicians should consider B. miyamotoi disease in the differential diagnosis. Our findings expand knowledge of the pathogen’s geographic distribution and highlight the need for enhanced surveillance and improved diagnostics to better define disease burden in Slovenia and neighboring countries.

Dr. Bogovič is an infectious diseases specialist in the Department of Infectious Diseases of the University Medical Center Ljubljana, Ljubljana, Slovenia. Her primary research interests are zoonoses, particularly tick-transmitted diseases.

Top

References

  1. Fukunaga  M, Takahashi  Y, Tsuruta  Y, Matsushita  O, Ralph  D, McClelland  M, et al. Genetic and phenotypic analysis of Borrelia miyamotoi sp. nov., isolated from the ixodid tick Ixodes persulcatus, the vector for Lyme disease in Japan. Int J Syst Bacteriol. 1995;45:80410. DOIPubMedGoogle Scholar
  2. Platonov  AE, Karan  LS, Kolyasnikova  NM, Makhneva  NA, Toporkova  MG, Maleev  VV, et al. Humans infected with relapsing fever spirochete Borrelia miyamotoi, Russia. Emerg Infect Dis. 2011;17:181623. DOIPubMedGoogle Scholar
  3. Hoornstra  D, Azagi  T, van Eck  JA, Wagemakers  A, Koetsveld  J, Spijker  R, et al. Prevalence and clinical manifestation of Borrelia miyamotoi in Ixodes ticks and humans in the northern hemisphere: a systematic review and meta-analysis. Lancet Microbe. 2022;3:e77286. DOIPubMedGoogle Scholar
  4. Hansford  KM, Wheeler  BW, Tschirren  B, Medlock  JM. Questing Ixodes ricinus ticks and Borrelia spp. in urban green space across Europe: a review. Zoonoses Public Health. 2022;69:15366. DOIPubMedGoogle Scholar
  5. Snegiriovaitė  J, Lipatova  I, Razgūnaitė  M, Paulauskas  A, Radzijevskaja  J. Prevalence and diversity of Borrelia spp. in questing ticks from urban green spaces in Lithuania. Ticks Tick Borne Dis. 2025;16:102512. DOIPubMedGoogle Scholar
  6. Šušnjar  J, Cerar Kisek  T, Strasek Smrdel  K, Ruzic-Sabljic  E, Adam  K, Ivovic  V. Detection, identification and genotyping of Borrelia spp. in ticks of Coastal-Karst and Littoral-Inner Carniola regions in Slovenia. Folia Parasitol. 2023;70:2023.007. DOIGoogle Scholar
  7. Cerar  T, Korva  M, Avšič-Županc  T, Ružić-Sabljić  E. Detection, identification and genotyping of Borrellia spp. in rodents in Slovenia by PCR and culture. BMC Vet Res. 2015;11:188. DOIPubMedGoogle Scholar
  8. Hoornstra  D, Stukolova  OA, van Eck  JA, Sokolova  MI, Platonov  AE, Hofhuis  A, et al. Exposure, infection and disease with the tick-borne pathogen Borrelia miyamotoi in the Netherlands and Sweden, 2007–2019. J Infect. 2024;89:106326. DOIPubMedGoogle Scholar
  9. Schwartz  T, Hoornstra  D, Øie  E, Hovius  J, Quarsten  H. Case report: first case of Borrelia miyamotoi meningitis in an immunocompromised patient in Norway. IDCases. 2023;33:e01867. DOIPubMedGoogle Scholar
  10. Dambietz  CA, Kintzinger  T, Schuler  F, Albers  A, Suntrup-Krueger  S, Fingerle  V, et al. Nanopore sequencing identifies Borrelia miyamotoi as an unexpected cause of meningitis after B cell depletion. Neuropathol Appl Neurobiol. 2024;50:e13017. DOIPubMedGoogle Scholar
  11. Fiecek  B, Szewczyk  T, Lewandowska  G, Chmielewski  T. Borrelia miyamotoi DNA in a patient suspected of Lyme borreliosis. Ann Agric Environ Med. 2025;32:1425. DOIPubMedGoogle Scholar
  12. Kubiak  JM, Klevay  M, Hilt  EE, Ferrieri  P. Acute meningoencephalitis associated with Borrelia miyamotoi, Minnesota, USA. Emerg Infect Dis. 2024;30:14724. DOIPubMedGoogle Scholar
  13. Slunečko  J, Kogoj  R, Zakotnik  S, Suljič  A, Knap  N, Bosilj  M, et al. Development and performance evaluation of a clinical metagenomics approach for identifying pathogens in the whole blood from patients with undifferentiated fever. Front Cell Infect Microbiol. 2025;15:1667422. DOIPubMedGoogle Scholar
  14. National Institute for Public Health. Monitoring infectious diseases transmitted by arthropods in Slovenia in 2024 [cited 2026 Feb 12]. https://nijz.si/publikacije/spremljanje-nalezljivih-bolezni-ki-jih-prenasajo-clenonozci-v-sloveniji-v-letu-2024
  15. Lotrič-Furlan  S, Rojko  T, Jelovšek  M, Petrovec  M, Avšič-Županc  T, Lusa  L, et al. Comparison of clinical and laboratory characteristics of patients fulfilling criteria for proven and probable human granulocytic anaplasmosis. Microbes Infect. 2015;17:82933. DOIPubMedGoogle Scholar

Top

Figure

Top

Suggested citation for this article: Bogovič P, Slunečko J, Kodre M, Kogoj R, Brecl MJ, Korva M, et al. Human cases of Borrelia miyamotoi disease, Slovenia, 2025. Emerg Infect Dis. 2026 Aug [date cited]. https://doi.org/10.3201/eid3208.260326

DOI: 10.3201/eid3208.260326

Original Publication Date: July 13, 2026

Table of Contents – Volume 32, Number 8—August 2026

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.

Top

Comments

Please use the form below to submit correspondence to the authors or contact them at the following address:

Petra Bogovič, University Medical Centre Ljubljana, Department of Infectious Diseases, Japljeva 2, 1000 Ljubljana, Slovenia

Send To

10000 character(s) remaining.

Top

Page created: June 25, 2026
Page updated: July 13, 2026
Page reviewed: July 13, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external